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We read with great interest the recent paper published by 
Jung et al. in Clinical Chemistry entitled “Cell-free SHOX2 
DNA methylation in blood as a molecular staging parameter for 
risk stratification in renal cell carcinoma patients: a prospective 
observational cohort study” (1).
They analyzed “SHOX2 mRNA expression in renal 
cell carcinoma (RCC) tissues and SHOX2 gene body 
methylation quantitatively in circulating cell-free 
DNA (ccfDNA) and RCC tissues with regard to risk 
stratification”. SHOX2 methylation in formalin-fixed 
and paraffin-embedded (FFPE) tumor tissue and in the 
corresponding plasma sample is strongly associated with 
an advanced tumor stage and risk of death after surgery. 
They observed that “Pretherapeutic SHOX2 ccfDNA 
methylation testing allows for the identification of RCC 
patients at high risk of death after nephrectomy. These 
patients might benefit from an adjuvant treatment or early 
initiation of a palliative treatment”. The prognostic value 
of SHOX2 methylation was evidenced in both tissue and 
plasma samples analysis. Hypermethylated SHOX2 patients 
experienced a worse overall survival compared to the 
hypomethylated, according to an optimized methylation 
cutoff (19.11%), established with regard to the greatest 
survival difference between methylation-negative and 
-positive patients (1).
SHOX2 and its role in tumorigenesis
The results presented by Jung et al. pave the way to 
numerous observations and comments. First of all, as also 
discussed by Jung and colleagues, the role of SHOX2 during 
tumorigenesis could be part of epithelial-to-mesenchymal 
transition (EMT) process via transforming growth factor 
β signaling (2,3). EMT is frequently observed in clear cell 
RCCs as the results of a sarcomatoid differentiation. A 
sarcomatoid phenotype in RCC has to be considered as 
grade 4 as reported in the WHO 2016 classification and 
it is positively associated with advanced stage and poor 
prognosis (4).
At single-cell level, EMT consists in a morphological 
transformation of RCC cells that leads to the loss of surface 
epithelial antigens and to the acquisition of mesenchymal 
features (i.e., vimentin expression) (5,6).
Liquid biopsy (LB) in RCC has received great attention 
for its potential prognostic and predictive value in helping 
clinicians to better understand the biology of the tumor and 
to personalize treatment in a non-invasive way (7). One of 
the most important limits in the application of LB in RCC 
194
Cimadamore et al. Renal cell carcinoma and liquid biopsy
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2019;7(Suppl 6):S194 | http://dx.doi.org/10.21037/atm.2019.07.30
Page 2 of 4
is the low sensitivity in the detection of circulating tumor 
cells (CTC) by Epithelial Marker-dependent isolation 
methods. Indeed, the loss of surface epithelial antigens 
during the EMT process prevent the possibility to capture 
CTCs. The implementation of other surface markers 
such as antibodies directed against membrane Carbonic 
anhydrase 9 (CA9/CAIX) and CD147 allows the isolation of 
a greater number of CTCs (8).
DNA methylation changes have been linked with 
stemness and metastasis in circulating tumor microemboli 
(CTMs). CTM, another promising entities detectable with 
LB, are defined as a group of cell, from two to more than 50 
CTCs, mixed with leukocytes, cancer-associated fibroblasts, 
endothelial cells, and platelets (9,10). The higher metastatic 
potential and their property to remain “dormant” for long 
period have been ascribed to a remarkable enrichment for 
stemness-related transcription factors that coordinately 
regulate proliferation and pluripotency. Differently, single 
CTCs featured hypomethylation of other transcription 
factor binding sites, including those that are occupied by 
MEF2C, JUN, MIXL1, and SHOX2, commonly enriched 
in various cancers (11).
Epigenome studies in liquid biopsy and 
genitourinary tumors
The current ccfDNA detection methods have demonstrated 
to be more efficient in the advanced stage setting rather 
than in cancer screening and the detection of minimal 
residual disease after treatment. Nonetheless, the presence 
of ccfDNA is not specific for a tumor condition. Indeed, 
high levels of ccfDNA have been found also in patients with 
acute blunt trauma, burn victimizes, sepsis, and myocardial 
infarction (12-14). ccfDNA quantification does not allow 
to discriminate which DNA fragments derived from cancer 
cells (circulating tumor DNA—ctDNA) or from a necrotic 
inflammatory process. In order to distinguish ctDNA from 
ccfDNA, novel detection strategies have been developed.
F l e i s c h h a c k e r  e t  a l .  s e t t l e d  a  n e w  s e n s i t i v e , 
immunoprecipitation-based protocol to explore the 
methylome of low quantities of ccfDNA. Cancer-specific 
differentially methylated regions (DMRs) allow ctDNA 
detection with high sensitivity, low-cost, and high-efficiency 
method (15). CpG island hypermethylation of ccfDNA 
in patients with RCC has been investigated as potential 
diagnostic biomarker by other authors. Hypermethylation 
on ccfDNA was found for the LRRC3B (74.1%), APC 
(51.9%), FHIT (55.6%), and RASSF1 (62.9%) genes in 
RCC patients (16).
Hauser et al. also demonstrated a higher methylation 
frequency in RCC patients compared to healthy individuals. 
The sensitivity of the methylation assay was low in single-
gene analysis, but combined analysis of methylation 
frequency of multiple genes (i.e., APC, PTGS2 and GSTP1) 
reached a sensitivity of 62.9% and a specificity of 87%. 
DNA hypermethylation of APC gene was associated with 
advanced cancer stage (17). 
Other genes such as SFRP1, BNC1, GREM1, RASSF1A, 
PCDH8, SCUBE3, GATA5, LAD1 and NEFH, promoter 
methylation has found to be associated with patient 
outcome, and their prognostic value was independently 
validated (18-20). Superior prognostic value has been 
obtained by combination of several markers as compared to 
the markers alone. Four-marker panel based on methylation 
level of GREM1, LAD1, NEFH and NEURL has proved 
to be able to identify patients with poorer survival in two 
independent patient series (21). The prognostic risk score 
based on a five-CpG-based-classifier developed by Wei and 
colleagues may be adopted to separate patients within the 
same clinical stage into subgroups with better and worse 
prognosis (22).
A diagnostic urine essay based on DNA methylation 
of OTX1, ONECUT2 and TWIST1 combined with 
mutation analysis in FGFR3, TERT and HRAS has been 
validated in patients with hematuria prior to cystoscopy. 
The area under the curve (AUC) obtained was of 0.96 with 
93% sensitivity and 86% specificity and an overall negative 
predictive value of 99%. An appropriate selection of 
patients candidate to cystoscopy by this predictive essay may 
lead to a reduction of costs and overtesting (23). Another 
important result has been obtained by the use of epigenetic 
essay in prostate cancer patients candidate to a re-biopsy 
after a prior negative biopsy. The methylation ratio of 3 
genes GSTP1, APC and RASSF1 were assessed in the FFPE 
from the initial biopsy. A negative predictive value of 88% 
was reached and the essay has proved to be an independent 
predictor of prostate cancer detection in a repeat biopsy (24).
ccfDNA compared to other liquid biopsy’ entities 
Compared with CTCs and CTMs, ccfDNA represents a 
better biomarker in terms of feasibility and reproducibility. 
Its half-life is less than 2 h and it is more stable than cells; 
ccfDNA is more sensitive than CTC Assay, and easily 
detectable. From a biological point of view, ctDNA is 
better biomarker in monitoring tumor dynamics showing 
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a greater correlation with changes in tumor burden. 
However, ctDNA in most cases requires a priori knowledge 
of the gene of interest and not all DNA mutations can be 
found. Whole exome sequencing (WES), splice variants, 
transcriptome analyses and functional assays can be 
performed only with CTC (25).
DNA methylation is a stable epigenetic mark and its 
quantification can be performed in both solid biopsy 
(i.e., FFPE tissue) and LB (i.e., blood, stool, and urine). 
Consequently, methylation analysis has considered a 
potential diagnostic, prognostic, and predictive biomarkers 
(26,27) (Figure 1).
Future perspectives and conclusions
Further studies are urgently needed in order to select 
specific genes of interest, or gene panels, and also 
to determine a validated optimized cut-off to better 
discriminate patients with higher risk of recurrence and 
metastatic progression. RCC may absolutely benefit from 
the development of non-invasive and reliable biomarkers, 
allowing early and timely personalized treatment changes. 
Many efforts for implementation of liquid biopsies are 
currently under examination along with emerging liquid 
biopsy entities (i.e., EVs, ccfRNAs, branched- chain amino 
acids (BCAAs), proteins, tumor- educated platelets). 
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